STOCK TITAN

Avinger Inc - AVGR STOCK NEWS

Welcome to our dedicated page for Avinger news (Ticker: AVGR), a resource for investors and traders seeking the latest updates and insights on Avinger stock.

Overview of Avinger Inc

Avinger Inc is a commercial-stage medical device company headquartered in Redwood City, California, that is redefining the treatment landscape for vascular disease. With its innovative image-guided and catheter-based systems, the company focuses on the diagnosis and treatment of peripheral artery disease (PAD) while also developing applications for coronary artery disease. The core of Avinger's technology is its proprietary Lumivascular platform, which integrates advanced optical coherence tomography (OCT) with therapeutic catheter systems to enable real-time, intravascular imaging and precision intervention.

Innovative Lumivascular Platform

Avinger's Lumivascular platform represents a significant evolution in the field of interventional medicine. By combining high-resolution OCT imaging with specialized catheter devices, physicians are empowered to visualize arterial structures from within, ensuring safer navigation and enhanced treatment precision. This unique image-guided approach addresses long-standing challenges in treating chronic total occlusions (CTOs) and complex PAD lesions, reducing the reliance on traditional X-ray imaging and subjective tactile feedback.

Product Suite and Clinical Applications

The company's product portfolio is designed to span the full spectrum of vascular interventions. Key components include:

  • Lightbox Imaging Console: A portable, high-definition imaging system that displays real-time OCT images.
  • Ocelot and Tigereye Catheters: A family of devices created to penetrate total arterial blockages, particularly targeting chronic total occlusions.
  • Pantheris Atherectomy Devices: The first image-guided atherectomy system specifically designed for precise plaque removal in PAD patients.

These devices not only facilitate more predictable procedural outcomes but also streamline the complex workflows typical of vascular interventions. The integration of advanced imaging ensures that physicians have comprehensive, intraprocedural visibility, which is critical when addressing both below-the-knee and above-the-knee lesions.

Competitive Landscape and Market Position

Avinger operates at the intersection of medical imaging and interventional therapy, a niche that requires extraordinary expertise in both engineering and clinical practice. Despite operating in a competitive medical device field, Avinger distinguishes itself through its sole focus on image-guided interventions. Its technology helps physicians achieve better procedural accuracy, potentially reducing operating times and enhancing patient safety. The company's methodical approach to innovation, combined with strategic partnerships and a robust patent portfolio, reinforces its position as a unique entity in the vascular therapy market.

Clinical Impact and Technological Advantages

The image-guided systems developed by Avinger are grounded in a deep understanding of vascular pathophysiology and interventional challenges. By offering real-time visualization during catheter-based procedures, the company addresses critical issues such as imprecise navigation and the risks associated with radiation exposure. This technological advantage provides a more intuitive and evidence-based approach to traversing occlusive lesions, thereby contributing to improved clinical outcomes. Additionally, the use of established reimbursement codes for various procedures facilitates smoother clinical adoption.

Commitment to Quality and Industry Expertise

Avinger's commitment to quality is evident in the rigorous design and development processes that underpin its products. The company continuously seeks to enhance its clinical evidence through robust studies and post-market evaluations. By integrating feedback from leading physicians and leveraging state-of-the-art imaging technologies, Avinger not only meets but often exceeds industry standards, bolstering its reputation for expertise and trustworthiness in the medical device community.

Conclusion

In summary, Avinger Inc offers a transformative approach to vascular disease treatment with its Lumivascular platform. The company's comprehensive suite of image-guided devices is tailored to address some of the most challenging aspects of interventional vascular therapy. Through innovation, strategic market positioning, and a clear focus on clinical excellence, Avinger continues to set new benchmarks in the diagnosis and treatment of both peripheral and coronary vascular diseases.

Rhea-AI Summary

Avinger, a commercial-stage medical device company, reported a revenue of $2.1 million for Q2 2022, marking a 13% increase from Q1 2022 but a decrease from $2.8 million in Q2 2021. The gross margin improved to 31%. The company launched the Lightbox 3 imaging console, filed a 510(k) for the Tigereye ST catheter, and advanced development of the Pantheris LV. Avinger maintained a cash position of $16 million and raised an additional $5 million in August 2022. The net loss for Q2 2022 was $4.2 million, a reduction from $5.1 million in Q1 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
-
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) announced a definitive agreement for a registered direct offering and private placement, totaling approximately $5 million in gross proceeds. The company will issue 1,484,019 shares of common stock and 1,369,864 shares in a private placement at a price of $1.752 per share. Avinger intends to use the net proceeds for working capital, R&D, and potentially acquiring complementary products. The offerings are expected to close around August 8, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
-
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) announced the submission of a 510(k) application to the FDA for its Tigereye ST catheter, an advanced system for treating Peripheral Artery Disease (PAD). This next-gen catheter features an innovative design that enhances crossing capabilities across chronic total occlusions (CTOs). With a working length of 140 cm, the device is compatible with 5 French sheaths, aiming to improve patient outcomes. CEO Jeff Soinski highlights that this device could significantly boost growth, building on a 47% increase the previous year in their CTO business.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
Rhea-AI Summary

Avinger, a medical device company focused on Peripheral Artery Disease (PAD), announced its expansion into the Chilean market with the launch of the Lumivascular product line.

The exclusive distribution agreement with Importadora y Distribuidora Arquimed Ltda will facilitate the sale of Avinger's Lightbox 3 imaging console and associated catheters. The Lightbox 3 is designed to enhance imaging capabilities during procedures, potentially improving patient outcomes without using ionizing radiation.

This move reflects Avinger's strategic growth and commitment to bringing innovative medical technologies to new regions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
-
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) showcased its Lumivascular technology at the Leipzig Interventional Course (LINC) 2022, held June 6-9, highlighting advancements in treating Peripheral Artery Disease (PAD). Key presentations by Dr. Arne Schwindt and Dr. Michael Lichtenberg emphasized the efficacy of the Pantheris OCT-guided atherectomy system in addressing in-stent restenosis with an impressive 93% freedom from target lesion revascularization at six months. A live case demonstrated successful treatment outcomes, reinforcing the technology's role in improving patient care while minimizing radiation exposure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
none
-
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) announced two podium presentations at the New Cardiovascular Horizons (NCVH) conference, featuring its Lumivascular technology for treating Peripheral Artery Disease (PAD). Key cardiologists highlighted Avinger's OCT-guided systems, demonstrating significant clinical results. Notably, the Pantheris SV showed 93% freedom from revascularization and 94% patency after 12 months. The technology enhances procedural safety and efficacy, reducing radiation exposure for healthcare workers. Avinger aims to revolutionize PAD treatment with its proprietary imaging devices.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
Rhea-AI Summary

Avinger, Inc. (Nasdaq:AVGR) held a significant presentation featuring its Lumivascular technology at the CLI Congress and Masterclass Münster in Germany. Dr. Arne Schwindt highlighted the effectiveness of the Pantheris OCT-guided atherectomy device in treating critical limb ischemia (CLI), showcasing successful patient outcomes. Avinger's platform is designed to provide real-time imaging during procedures, enhancing the precision of treatment for Peripheral Artery Disease (PAD). Avinger aims to reduce amputations through its innovative approach, which currently addresses a significant global health issue affecting over 200 million people.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
none
-
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) reported first-quarter 2022 revenue of $1.9 million, down from $2.6 million in the same period last year, impacted by COVID-19-related hospital staffing shortages. The gross margin decreased to 28%, compared to 35% in Q1 2021. Operating expenses slightly reduced to $5.2 million, while the net loss remained consistent at $5.1 million. The company maintained a cash position of $20.0 million, bolstered by a $7.6 million capital raise in January 2022. Avinger has launched its Lightbox 3 imaging console and is progressing with new catheter developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.35%
Tags
none
-
Rhea-AI Summary

Avinger, Inc. (Nasdaq: AVGR) will announce its Q1 2022 financial results on May 10, 2022, after market close. The company, focused on Peripheral Artery Disease (PAD)Avinger's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) announced the full commercial availability of its Lightbox 3 imaging console, designed to enhance vascular disease treatment. Following FDA's 510(k) clearance in January, the product has been used at 12 clinical sites with positive physician feedback. The Lightbox 3 offers high-definition imaging, reducing reliance on contrast dye and improving operational efficiency. Its portability aims to accelerate new user adoption, contributing to increased productivity for Avinger's field teams and promoting device utilization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none

FAQ

What is the current stock price of Avinger (AVGR)?

The current stock price of Avinger (AVGR) is $0.474 as of February 17, 2025.

What is the market cap of Avinger (AVGR)?

The market cap of Avinger (AVGR) is approximately 1.5M.

What is Avinger Inc's primary business?

Avinger Inc develops image-guided, catheter-based systems for diagnosing and treating vascular diseases, including peripheral and coronary artery conditions.

What is the Lumivascular platform?

The Lumivascular platform is Avinger's proprietary technology that integrates OCT imaging with therapeutic catheters, allowing real-time visualization during vascular interventions.

Which vascular conditions do Avinger's products target?

Avinger's devices are primarily used for treating peripheral artery disease and managing complex conditions such as chronic total occlusions and coronary artery blockages.

How does Avinger's technology benefit physicians?

By providing high-resolution, real-time imaging inside the artery, physicians can accurately navigate devices, reduce reliance on traditional X-ray imaging, and achieve more predictable outcomes.

What makes Avinger's approach unique in the medical device market?

Avinger stands out with its exclusive focus on image-guided interventions, offering a technological edge through its integrated OCT system and specialized catheter designs that enhance procedural safety.

What products are included in Avinger's portfolio?

The portfolio includes the Lightbox imaging console, the Ocelot and Tigereye series of CTO catheters, and the Pantheris atherectomy devices designed for the treatment of PAD.

How does Avinger address the challenges of vascular interventions?

By employing a real-time, image-guided approach, Avinger improves device navigation and plaque removal, thereby streamlining complex procedures and enhancing clinical results.

In what ways does Avinger demonstrate industry expertise?

Avinger combines rigorous R&D, a strong patent portfolio, clinical collaborations, and strategic partnerships to reinforce its authority and trustworthiness in the field of vascular therapy.
Avinger Inc

Nasdaq:AVGR

AVGR Rankings

AVGR Stock Data

1.52M
3.05M
7.94%
10.16%
4.13%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
REDWOOD CITY